MarketCap
Facebook
X
Telegram
SELLAS Life Sciences Group Balance Sheet 2025-2009 | SLS
Brief overview of SELLAS Life Sciences Group's balance sheet strength
This overview follows the five latest available annual observations between 2021 and 2025.
Assets reached $78.3 million, compared with $26.3 million at the beginning. Growth of +198.2% and CAGR near 31.4% show active expansion.
Assets outpaced liabilities, +198.2% versus +26.1%. Dependence on external funding declined.
Equity funds 90.5% of assets versus 77.4% initially. This creates a conservative balance sheet structure.
The balance sheet holds more cash than interest-bearing debt; net debt is -$70.8 million, indicating minimal leverage.
Cash equals 91.6% of the balance sheet, compared with 81.3% five periods ago. This is the readily available cushion.
Retained earnings are negative at -$275 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Overall picture
SELLAS Life Sciences Group has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.
Annual Balance Sheet SELLAS Life Sciences Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-70.8 M | -12.9 M | -1.62 M | -16.2 M | -20.5 M | -33.7 M | -7.06 M | -5.34 M | 8.67 M | -1.69 M | -25 M | -15.2 M | -37.9 M | -32.8 M | -10.9 M | - | - |
Long Term Debt |
457 K | 457 K | 460 K | 573 K | 610 K | 825 K | - | - | 2.61 M | - | - | 4.49 M | 7.74 M | - | - | - | - |
Long Term Debt Current |
544 K | 544 K | 446 K | 372 K | 198 K | 166 K | 217 K | - | 8.38 M | 16.4 M | 4.74 M | 3.91 M | 2.15 M | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 825 K | 5.23 M | 5.7 M | 6.89 M | 6.76 M | 11.6 M | 16.2 M | 19.6 M | 11.3 M | 9.65 M | - | - |
Total Current Liabilities |
7.02 M | 9.51 M | 13.7 M | 15.5 M | 4.98 M | 12.3 M | 5.29 M | 5.97 M | 24.6 M | 30.4 M | 57.1 M | 27.2 M | 62.5 M | 15.9 M | 11.2 M | 5.03 M | - |
Total Liabilities |
7.47 M | 9.97 M | 14.2 M | 16.1 M | 5.93 M | 18.1 M | 10.5 M | 11.7 M | 31.5 M | 37.2 M | 68.6 M | 43.4 M | 82.1 M | 27.2 M | 20.9 M | 5.05 M | - |
Deferred Revenue |
- | - | - | - | - | 5.6 M | - | - | - | - | - | - | - | - | 816 K | - | - |
Retained Earnings |
-275 M | -248 M | -217 M | -180 M | -139 M | - | -101 M | -81.9 M | -54.2 M | -303 M | -279 M | -215 M | -179 M | -102 M | -67.2 M | - | - |
Total Assets |
78.3 M | 19.4 M | 6.22 M | 20.9 M | 26.3 M | 46 M | 16.6 M | 16.9 M | 33.5 M | 65.8 M | 82.1 M | 80.5 M | 88 M | 55 M | 31 M | 7.48 M | - |
Cash and Cash Equivalents |
71.8 M | 13.9 M | 2.53 M | 17.1 M | 21.4 M | 35.3 M | 7.28 M | 5.34 M | 2.32 M | 18.1 M | 29.7 M | 23.6 M | 47.8 M | 32.8 M | 32.8 M | 6.89 M | 5.68 M |
Book Value |
70.9 M | 9.46 M | -7.98 M | 4.85 M | 20.3 M | 28 M | 6.09 M | 5.24 M | 2.07 M | 28.7 M | 13.5 M | 37.1 M | 5.89 M | 27.8 M | 10.1 M | 2.43 M | - |
Total Shareholders Equity |
70.9 M | 9.46 M | -7.98 M | 4.85 M | 20.3 M | 28 M | 6.09 M | 5.24 M | 2.07 M | 28.7 M | 13.5 M | 37.1 M | 5.89 M | 27.8 M | 10.1 M | 2.43 M | - |
All numbers in USD currency
Quarterly Balance Sheet SELLAS Life Sciences Group
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
457 K | 309 K | 457 K | - | 157 K | 309 K | 457 K | - | 161 K | 313 K | 460 K | 178 K | 302 K | 422 K | 573 K | 680 K | 783 K | 883 K | 610 K | 667 K | 721 K | 775 K | 825 K | 825 K | 825 K | 825 K | - | - | - | 112 K | - | - | - | 1.15 M | 2.61 M | 2.61 M | 2.61 M | 2.61 M | 5.66 M | - | - | - | - | 1.53 M | 2.55 M | 3.53 M | 4.49 M | 4.49 M | 4.49 M | 4.49 M | 7.74 M | 7.74 M | 7.74 M | 7.74 M | - | - | - | - | - | - | - | - |
Total Liabilities |
7.47 M | 6.76 M | 9.97 M | 5.92 M | 6.16 M | 7.2 M | 9.97 M | 10.6 M | 12.2 M | 14.8 M | 14.2 M | 11.9 M | 13.7 M | 15.9 M | 16.1 M | 13.4 M | 13.2 M | 17.4 M | 5.93 M | 11.3 M | 10.2 M | 11.8 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 31.5 M | 31.5 M | 31.5 M | 31.5 M | 11.4 M | 37.2 M | 37.2 M | 37.2 M | 68.6 M | 68.6 M | 68.6 M | 68.6 M | 43.4 M | 43.4 M | 43.4 M | 43.4 M | 82.1 M | 82.1 M | 82.1 M | 82.1 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 900 K | 5.6 M | 5.6 M | 5.6 M | 5.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 816 K | 877 K | 578 K | - |
Retained Earnings |
-275 M | -283 M | -248 M | -267 M | -261 M | -254 M | -248 M | -241 M | -234 M | -227 M | -217 M | -209 M | -200 M | -191 M | -180 M | -171 M | -164 M | -155 M | -139 M | -132 M | -125 M | -120 M | -118 M | -118 M | -118 M | -118 M | -101 M | -101 M | -101 M | -101 M | -81.9 M | -81.9 M | -81.9 M | -81.9 M | -54.2 M | -54.2 M | -54.2 M | -54.2 M | -30.4 M | -303 M | -303 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -61 M | - |
Total Assets |
78.3 M | 114 M | 19.4 M | 51.6 M | 32.3 M | 35 M | 19.4 M | 26.5 M | 15.1 M | 24.4 M | 6.22 M | 8.09 M | 18.6 M | 29.1 M | 20.9 M | 26 M | 32.2 M | 21.4 M | 26.3 M | 38 M | 43.6 M | 40.6 M | 46 M | 46 M | 46 M | 46 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 6.42 M | 65.8 M | 65.8 M | 65.8 M | 82.1 M | 82.1 M | 82.1 M | 82.1 M | 80.5 M | 80.5 M | 80.5 M | 80.5 M | 88 M | 88 M | 88 M | 88 M | 55 M | 55 M | 55 M | 55 M | 31 M | 31 M | 31 M | 31 M |
Cash and Cash Equivalents |
14 M | 107 M | 2.63 M | 44.3 M | 25.3 M | 28.4 M | 13.9 M | 21.1 M | 9.25 M | 18.5 M | 2.53 M | 4.07 M | 13.9 M | 24 M | 17.1 M | 21.4 M | 27.1 M | 14.4 M | 21.4 M | 26.4 M | 30 M | 28 M | 35.3 M | 35.3 M | 35.3 M | 35.3 M | 7.28 M | 7.28 M | 7.28 M | 7.28 M | 5.34 M | 5.34 M | 5.34 M | 5.34 M | 2.32 M | 2.32 M | 2.32 M | 2.32 M | 5.96 M | 18.1 M | 18.1 M | 18.1 M | 1.4 M | 29.7 M | 29.7 M | 29.7 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 47.8 M | 47.8 M | 47.8 M | 47.8 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 47.8 M | 11.4 M | 11.4 M | 11.4 M |
Book Value |
70.9 M | 107 M | 9.46 M | 45.6 M | 26.1 M | 27.8 M | 9.46 M | 15.9 M | 2.91 M | 9.68 M | -7.98 M | -3.83 M | 4.84 M | 13.2 M | 4.85 M | 12.6 M | 19.1 M | 4.02 M | 20.3 M | 26.6 M | 33.4 M | 28.7 M | 28 M | 28 M | 28 M | 28 M | 6.09 M | 6.09 M | 6.09 M | 6.09 M | 5.24 M | 5.24 M | 5.24 M | 5.24 M | 2.07 M | 2.07 M | 2.07 M | 2.07 M | -5 M | 28.7 M | 28.7 M | 28.7 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 37.1 M | 37.1 M | 37.1 M | 37.1 M | 5.89 M | 5.89 M | 5.89 M | 5.89 M | 27.8 M | 27.8 M | 27.8 M | 27.8 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M |
Total Shareholders Equity |
9.46 M | 107 M | -7.98 M | 45.6 M | 26.1 M | 27.8 M | 9.46 M | 15.9 M | 2.91 M | 9.68 M | -7.98 M | -3.83 M | 4.84 M | 13.2 M | 4.85 M | 12.6 M | 19.1 M | 4.02 M | 20.3 M | 26.6 M | 33.4 M | 28.7 M | 28 M | 28 M | 28 M | 28 M | 6.09 M | 6.09 M | 6.09 M | 6.09 M | 5.24 M | 5.24 M | 5.24 M | 5.24 M | 2.07 M | 2.07 M | 2.07 M | 2.07 M | -5 M | 28.7 M | 28.7 M | 28.7 M | -12.3 M | 13.5 M | 13.5 M | 13.5 M | 37.1 M | 37.1 M | 37.1 M | 37.1 M | 5.89 M | 5.89 M | 5.89 M | 5.89 M | 27.8 M | 27.8 M | 27.8 M | 27.8 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of SELLAS Life Sciences Group, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
